Key facts
- Geneplus Technology’s last known valuation is $604.6M (Nov 2025).
- It has raised $186.1M; the latest was IPO in Dec 2025.
- Notable investors include Fortune Capital, Co-Stone Capital, Green Pine Capital Partners, Baidu Ventures, Highlight Capital — 27 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Geneplus Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Geneplus Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Geneplus Technology
Provider of gene sequencing and detection services intended for hospitals, research institutions, and pharmaceutical companies. The company's services provide integrated clinical and technological solutions, including tumor gene monitoring and detection, genetic testing and sequencing, and cancer genomics analysis, enabling medical practitioners to accurately and effectively detect, control, and prevent potential cancer-related risks.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Employees
- 810
- Website
- geneplus.cn/
- Ownership
- In IPO Registration
Geneplus Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Geneplus Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Geneplus Technology in its N-PORT filings yet. We sweep new filings monthly.